Bank of New York Mellon Corp Buys 19,811 Shares of Celcuity Inc. (NASDAQ:CELC)

Bank of New York Mellon Corp increased its position in shares of Celcuity Inc. (NASDAQ:CELC) by 42.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,256 shares of the company’s stock after acquiring an additional 19,811 shares during the quarter. Bank of New York Mellon Corp owned about 0.19% of Celcuity worth $1,085,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Commodore Capital LP boosted its position in shares of Celcuity by 3.6% during the fourth quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock worth $25,566,000 after purchasing an additional 60,563 shares in the last quarter. Baker BROS. Advisors LP lifted its holdings in Celcuity by 189.9% during the first quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock worth $33,534,000 after acquiring an additional 1,017,000 shares in the last quarter. Perceptive Advisors LLC acquired a new position in Celcuity in the fourth quarter valued at about $21,583,000. Vanguard Group Inc. increased its holdings in shares of Celcuity by 1.0% in the first quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock worth $17,898,000 after acquiring an additional 7,821 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Celcuity during the first quarter worth about $3,545,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CELC shares. Leerink Partnrs raised Celcuity to a “strong-buy” rating in a research note on Monday, July 22nd. Stifel Nicolaus lowered their price objective on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. Leerink Partners began coverage on shares of Celcuity in a research report on Monday, July 22nd. They issued an “outperform” rating and a $29.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Celcuity in a research report on Thursday, August 15th. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a report on Thursday, August 15th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Celcuity currently has an average rating of “Buy” and a consensus price target of $28.67.

Celcuity Price Performance

Shares of CELC opened at $14.85 on Friday. The business has a 50-day simple moving average of $16.66 and a two-hundred day simple moving average of $16.90. Celcuity Inc. has a 12-month low of $8.39 and a 12-month high of $22.19. The stock has a market cap of $521.25 million, a PE ratio of -5.34 and a beta of 0.76. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same quarter in the prior year, the firm posted ($0.66) earnings per share. Analysts anticipate that Celcuity Inc. will post -2.54 earnings per share for the current fiscal year.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.